Page 37 - Expanded Access News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA USA - English Share this article Share this article CARMIEL, Israel and BOSTON, April 28, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an internat...

Secondary Mktg., AE Jobs; Workflow, Payment, Doc Tools; Company Sponsored Events; VA and FHA Updates Apr 27 2021, 8:18AM When I was a kid, I did things like eat Wonder Bread. I still enjoy a McDonald’s cheeseburger on occasion. As a kid I remember sharing a Coke with the kids on my street between hoops games, having a bite of a buddy’s cookie, or merely rinsing off a scratch with hose water. Now there are some that tell you you’ll die from doing any of those. Things are always in transition. There’s the possibility of the transition from WFH (work from home)...

email article Biogen will launch an expanded access program for its investigational amyotrophic lateral sclerosis (ALS) drug tofersen in July -- but that's likely too late for the patient whose quest to try the therapy has brought it into the spotlight. In a "community update" posted to its website, Biogen said it will offer compassionate use to the "most rapidly progressing patients" starting in mid-July, once placebo patients in its phase III trial are transitioned to active therapy. The company noted that this would be "before the drug has been confirmed to be safe and effective." ...

Vitro Diagnostics, Inc.: Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter st, 2021, financial results of operations. Vitro Biopharma recorded quarter ended January 31 st, 2021 revenues of $ 127,492 vs $225,921 a decrease of 44% over the prior comparative quarter directly attributed to the COVID-19 pandemic. Revenues in the first quarter of 2021 of $127,492 were down 21% over the $161,888 recorded in the prior fourth quarter. The decrease in the current first quarter revenue was on account of the Research products weak seasonal qu...

The Worldwide Virtual Clinical Trials Industry is Expected to Reach $10 Billion by 2026 News provided by Share this article Share this article ResearchAndMarkets.com's offering. The Global Virtual Clinical Trials Market size is expected to reach $10 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. Virtual Clinical Trials (VCTs) are also known as remote or decentralized trails, are a comparatively new but still underused technique of carrying out clinical research taking complete benefit of technologies like apps, online social interaction platforms, and ele...